Search the Newsreel

Sarepta Therapeutics (SRPT) Tightened 2026 Revenue Guidance, Is The Stock Still A Bargain?

Sarepta Therapeutics recently tightened its 2026 revenue guidance to $1.2 billion to $1.3 billion and announced second-quarter results and pipeline updates. Despite a 15.38% share price jump over the last 7 days, the stock is down 13.75% year-to-date and 83.87% over three years. Analysts …

Sarepta Therapeutics (SRPT) sees 5.05% ownership reported by AQR in 13G/A

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have reported a beneficial ownership of 5,329,691 shares, or 5.05%, of Sarepta Therapeutics, Inc. common stock as of June 30, 2026. This reported amount includes 1,004,002 shares represented by Convertible Notes. Both entities share …

Massachusetts Biotech's Flagship Gene Therapy Posts Fifth Straight Quarterly Decline as Muscular Dystrophy Data Loom

Sarepta Therapeutics (SRPT) saw its flagship gene therapy, ELEVIDYS, experience a fifth consecutive quarterly revenue decline, with analysts from H.C. Wainwright & Co. reiterating a Sell rating and a $5.00 price target. Despite this, the market reaction was muted, suggesting investors are assigning significant …

SRPT|Sarepta Therapeutics Inc|Price:17.890|Chg%:-0.530

Sarepta (SRPT) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Senior Director of Investor Relations - Tamara Thornton Chief Executive Officer - Michael E. Severino President of R&D and Technical Operations - Dr. Louise Rodino-Klapac Chief Commercial Officer …

Assenagon Asset Management S.A. Makes New $8.16 Million Investment in Sarepta Therapeutics, Inc. $SRPT

Assenagon Asset Management S.A. has initiated a new $8.16 million investment in Sarepta Therapeutics (NASDAQ:SRPT), acquiring 454,375 shares, which represents approximately 0.43% of the company. Institutional investors and hedge funds collectively own about 86.68% of SRPT. Despite mixed analyst ratings, with a consensus "Hold" …

SRPT Stock Plunges 7% After-Hours As Elevidys Demand Slumps — CEO Still Sees Return To Growth

Dimensional Fund Advisors LP Sells 121,412 Shares of Sarepta Therapeutics, Inc. $SRPT

Dimensional Fund Advisors LP significantly reduced its stake in Sarepta Therapeutics, Inc. by selling 121,412 shares, leaving them with 336,736 shares valued at $7.3 million. Despite institutional investors owning a large portion of the company and some increasing their positions, analyst sentiment is mixed, …

Sarepta Therapeutics, Inc. (SRPT) Investor Outlook: Analyzing The 31.63% Potential Upside

Sarepta Therapeutics (SRPT) is a biotechnology firm focusing on RNA-targeted therapeutics and gene therapies for rare diseases like Duchenne muscular dystrophy, with a market capitalization of $1.77 billion. Despite a revenue decline of 34.30% and negative EPS, analysts project a 31.63% potential upside, driven …

Why Sarepta Therapeutics (SRPT) Is Up 12.9% After Cutting 2026 Guidance And Naming A New CEO

Sarepta Therapeutics' stock rose 12.9% despite cutting its 2026 revenue guidance to US$1.20 billion–US$1.30 billion and reporting lower Q2 2026 revenue of US$401.25 million, alongside a net loss. The company appointed Michael Severino, M.D., as the new CEO, a move seen as a positive …

Price to earnings forward of Sarepta Therapeutics, Inc. – BX:AB3A

This article provides financial data for Sarepta Therapeutics, Inc. under the ticker BX:AB3A on the BX Swiss exchange. It specifically highlights the "Price to earnings forward" metric for the company. The page appears to be a financial data snippet from TradingView, focusing on market …

Sarepta Therapeutics, Inc. Revenue Breakdown – BX:AB3A

Sarepta Therapeutics, Inc. (BX:AB3A) generated 1.74 billion CHF in revenue last year, primarily from its RNA-targeted Therapeutics, Small Interfering RNA Platform, Gene Therapy, and Other Genetic Therapeutic Modalities segment, which contributed 1.48 billion CHF. The United States was the largest regional contributor, accounting for …

Sarepta Therapeutics (SRPT) Brings In Michael Severino As Chief Executive Officer

Sarepta Therapeutics has appointed Michael Severino as its new Chief Executive Officer and a member of its Board of Directors. Severino, with a strong background in senior leadership and research in biotech, joins the company as it navigates a revenue reset, with Q2 2026 …

Noticias de acciones de Sarepta Therapeutics Inc (SRPT)

Sarepta Therapeutics (SRPT) Stock Rally Hinges On Profit Progress And Revenue Drop

Sarepta Therapeutics (SRPT) shares rose 5% after its Q2 2026 earnings report, despite a significant revenue drop, due to the company reporting positive GAAP operating income and tightening its full-year guidance. Investors see this as confirmation of the company's path to profitability, transitioning from …

Empowered Funds LLC Has $2.48 Million Stake in Sarepta Therapeutics, Inc. $SRPT

Empowered Funds LLC significantly increased its stake in Sarepta Therapeutics (NASDAQ:SRPT) by 1,898,816.7% in Q1, holding 113,935 shares valued at $2.48 million. Other institutional investors also adjusted their positions, and collective institutional ownership stands at 86.68%. Despite the company beating Q2 earnings and revenue …

Sarepta Faces Competitive Pressures Despite Pipeline Updates, RBC Says

Sarepta Therapeutics (SRPT) is seeing a new strategic focus under its recently appointed CEO, with m PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …

Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated

Sarepta Therapeutics (SRPT) reported Q2 2026 adjusted earnings and total revenues that beat analyst estimates, despite a significant year-over-year decline in both figures, primarily due to lower Elevidys sales. The company updated its 2026 net product revenue guidance and raised its collaboration and other …

Sarepta’s new CEO Michael Severino faces critical milestones to prove growth

Sarepta Therapeutics' new CEO, Michael Severino, is navigating critical upcoming milestones that will determine the company's growth trajectory, including regulatory decisions for its Duchenne muscular dystrophy gene therapy Elevidys and exon-skipping treatments. Elevidys sales saw a sequential drop, though patient enrollment forms are increasing, …

Sarepta Narrows 2026 Revenue Guidance on Elevidys Q2 Sales Dip

Sarepta Therapeutics reported a 34 percent decline in Q2 2026 revenue, primarily due to lower sales of its Duchenne muscular dystrophy gene therapy, Elevidys, following an FDA label narrowing last year. Despite this, the company beat Wall Street's revenue and EPS estimates. Sarepta has …

Sarepta Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:SRPT) 2026-08-06

Sarepta Therapeutics reported strong financial performance in Q2 2026, with GAAP operating income of $13 million and non-GAAP operating income of $86 million, and cash and investments growing to $945 million. The company narrowed its 2026 net product revenue guidance to $1.2 billion-$1.3 billion …

Sarepta forecasts $1.2B-$1.3B 2026 net product revenue as Cohort 8 12-week data shifts to Q1 2027

Earnings Call Insights: Sarepta Therapeutics (SRPT) Q2 2026 MANAGEMENT VIEW * “This is my first earnings call as CEO of Sarepta...” and “we have narrowed 2026 total net product revenue guidance to $1.2 billion to $1.3 billion, with a mid-point being the appropriate reference,” …

Sarepta Therapeutics, Inc. Q2 2026 Earnings Call Summary

Sarepta Therapeutics, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Execution and Platform Evolution Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap …

Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics

Sarepta Therapeutics (SRPT) reported $401.25 million in revenue for the quarter ended June 2026, representing a year-over-year decline of 34.3%. EPS of $0.64 for the same period compares to $2.02 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $355.55 …

Informe de resultados de Sarepta: supera las estimaciones del segundo trimestre de 2026 y sus acciones suben en el mercado fuera de horario

Sarepta Therapeutics Q2 2026 Earnings Call Transcript

Sarepta Therapeutics reported strong financial performance in Q2 2026, with GAAP operating income of $13 million and non-GAAP operating income of $86 million, and cash and investments growing to $945 million. The company narrowed its 2026 net product revenue guidance to $1.2 billion-$1.3 billion …

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

New CEO Michael Severino, MD, brings extensive biopharma leadership and a proven track record of advancing innovation, building franchises, and delivering growth Net product revenues for the second quarter 2026 totaled $328.7 million, consisting of $230.6 million of PMO net product revenue and $98.1 …

Sarepta Therapeutics Navigates FDA Hold on Elevidys in Expanding DMD Market

Sarepta Therapeutics is facing an FDA clinical hold on its Duchenne muscular dystrophy (DMD) therapy, Elevidys, due to safety concerns over acute liver failure, even as the global DMD market is projected to reach US$62.13 billion by 2030. Despite the hold, Sarepta has five …

Sarepta set to report earnings as new CEO faces ELEVIDYS test

Sarepta Therapeutics is poised to release its second-quarter earnings, with investors keenly observing the performance of its gene therapy ELEVIDYS under new CEO Michael Severino. The company faces scrutiny over whether ELEVIDYS sales can stabilize after a recent decline and safety concerns, impacting market …

Sarepta Therapeutics (NASDAQ: SRPT) swings to Q2 loss, details ELEVIDYS

Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates

Sarepta Therapeutics Inc expected to post earnings of 26 cents a share - Earnings Preview

Sarepta Therapeutics Inc is projected to report earnings of 26 cents per share. This information is based on an earnings preview from Refinitiv, indicating upcoming financial disclosures for the company.

Sarepta Therapeutics (SRPT) Names A New CEO, Is The Stock Cheap?

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Sarepta Therapeutics (SRPT) has drawn fresh attention after filing a US$39.7 million shelf registration tied to an employee stock ownership plan, alongside appointing …